Verismo Therapeutics

Verismo Therapeutics

Biotechnology Research

Philadelphia, Pennsylvania 4,547 followers

The team that invented the first FDA-approved CAR-T therapy is back to revolutionize the space with the KIR-CAR.

About us

Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options. Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells. Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.

Industry
Biotechnology Research
Company size
11-50 employees
Headquarters
Philadelphia, Pennsylvania
Type
Privately Held
Founded
2020
Specialties
CAR-T, Cell Therapy, Solid Tumor, Immuno-Oncology, and KIR-CAR Platform

Locations

  • Primary

    3675 Market St

    Suite 200

    Philadelphia, Pennsylvania 19104, US

    Get directions

Employees at Verismo Therapeutics

Updates

Similar pages

Browse jobs

Funding

Verismo Therapeutics 4 total rounds

Last Round

Grant

US$ 150.0K

Investors

ScaleReady
See more info on crunchbase